Convalescent Plasma for the Treatment of Severe COVID-19

Massimo Franchini
Giancarlo Maria Liumbruno

Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy

Abstract: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.

Keywords: SARS-CoV-2, COVID-19, hyperimmune plasma, convalescent plasma, therapy

Introduction

Coronavirus (CoV), an enveloped single-stranded RNA virus belonging to the family of Coronaviridae, which initially caused enzootic infections, has been shown in the last decades to be capable of crossing the species barrier and infecting humans.1,2 Two outbreaks of coronaviruses in humans have occurred since the beginning of the second millennium, causing Severe Acute Respiratory Syndrome (SARS-CoV) in 2002 and Middle East Respiratory Syndrome (MERS-CoV) in 2012.3–5 In December 2019, the third outbreak of a rapidly transmitted coronavirus, named SARS-CoV-2, emerged. This novel coronavirus causes a syndrome including pneumonia, which was later named Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO).6

SARS-CoV-2 was first discovered in the city of Wuhan, China, and spread rapidly to many countries. On March, 11 2020, the WHO declared that the infection was a global pandemic.7 This new virus posed a major challenge among physicians because it had no specific pre-existing therapy. As a consequence, the therapeutic efforts were initially focused on optimizing respiratory care, managing thrombotic and inflammatory complications by using anticoagulation and corticosteroids, and repurposing existing antiviral therapies (eg, hydroxychloroquine, lopinavir/ritonavir and remdesivir). Despite anecdotal evidence, designs of clinical trials have not concluded that a statistically significant effect occurs in patient cohorts analyzed thus far.8–10 Considering the lack of effective anti-SARS-CoV-2 drugs and the initial positive experience from China,10,11 convalescent plasma (CP), an old therapy used with apparent success in many epidemics and outbreaks since the 1918 Spanish flu,12–15 was proposed again also for COVID-19.
In this narrative review, after a presentation of the most plausible mechanisms of action of CP, we critically discuss the main literature results on the use of CP as a treatment for severe COVID-19.

As a search literature strategy, the Medline and PubMed electronic database was searched on this topic. The Medical Subject Heading and keywords used were: “convalescent plasma”, “hyperimmune plasma”, “therapy”, “SARS-CoV-2”, “COVID-19”, “safety” and “efficacy”. We also screened the reference lists of the most relevant review articles for additional studies not identified in the initial literature search.

**Mechanisms of Action of Convalescent Plasma**

The antiviral properties of CP are undoubtedly mostly due to the presence of neutralizing antibodies directed against the SARS-CoV-2 membrane spike protein, which mediates the attachment between the virus and host cell surface ACE2 receptors, facilitating viral entry into the host cell. These antibodies are therefore passively transferred through CP transfusion from recovered donors to COVID-19-affected recipients, who are not able to generate a sufficient immune response (passive immunity). Indeed, a number of studies have associated the efficacy of CP therapy, measured by improvement in clinical presentation and the decreased viral load, with the concentration of neutralizing antibodies in plasma from recovered donors. A similar mechanism was also observed when CP was used during the previous SARS-CoV and MERS outbreaks. In addition, other immunomodulatory actions linked to the passive antibody transfer by CP infusion, able to interfere with complement activation, antibody-dependent cellular toxicity and phagocytosis, may help to limit the inflammatory cascade, which is well known to have often more deleterious effects than the virus itself. The neutralizing activity of plasma for SARS-COV2 is measured by the ability of its highest dilution to reduce 50% of viral plaques in culture compared to control plasma. The virus neutralization by plaque reduction assay is currently the gold standard method for the determination of viral neutralizing antibody titers; this test, however, not widely available because it is labor-intensive, time-consuming (3–5 days) and requires a biosafety level 3 laboratory. To overcome these difficulties, a number of surrogate neutralization assays, utilizing ELISA or other serological test methods to measure antibody titers, have been developed. Although the majority of studies have demonstrated a high degree of correlation between antibody titers measured with immunoassays and virus neutralization assay, the concordance is not absolute and carries some degrees of discrepancy.

Finally, a completely different pathogenic mechanism, involving the ABO blood group system, has been proposed recently. There is a hypothesis that people with O blood type are less susceptible to SARS-CoV-2 infection than those with non-O blood groups. This possible difference in susceptibility might be related to the presence of IgG anti-A isoagglutinins in O blood group subjects, which would prevent the binding of SARS-CoV-2 to its receptor thereby inhibiting the virus from entering into the targeted human cells.

All in all, the mechanism at the basis of the clinical efficacy of CP is not completely understood and deserves further research. Nevertheless, it is reasonable that multiple mechanistic pathways may be contemporarily involved acting separately or, more probably, in a synergic way.

**Literature Results**

**Clinical Trials**

First used against SARS-CoV-2 in China and Italy, CP was rapidly deployed in many countries. Table 1 reports the characteristics of the main studies evaluating the safety and efficacy of CP in COVID-19 patients. Duan and colleagues presented a series of ten severely ill COVID-19 patients, all of whom were given a 200 mL transfusion of CP, containing high titers of neutralizing antibody (>1:640), at a median of 16.5 days after the onset of illness. The primary endpoint was safety, which was demonstrated by the fact that all patients tolerated the CP transfusion well and none had severe adverse events. The secondary endpoints included improvements in clinical symptoms and laboratory values from day 3 after CP infusion. Reported effects of the CP transfusion included increases in neutralizing antibody titer, oxygen saturation and lymphocyte count and decreases in C-reactive protein (CRP), SARS-CoV-2 viral load and lung lesions on chest radiograms.

In a proof-of-concept, one-arm, multicenter, interventional study, Perotti and colleagues observed the effects of CP infusion in 46 severe COVID-19 patients in the short-term (7 days) period. Improvement in clinical and chest radiogram severity, laboratory values (CRP, ferritin and lactate dehydrogenase [LDH]) and functional respiratory parameters (partial pressure of arterial oxygen to fraction of inspired oxygen ratio [P\textsubscript{A}O\textsubscript{2}/F\textsubscript{I}O\textsubscript{2}]) were observed at the 7-day follow-up. A significant reduction of mortality rate (from 15% to 6.5%) was observed comparing the mortality data with those of an historical cohort group.
Table 1 Characteristics of the Main Studies Evaluating the Role of Convalescent Plasma in COVID-19 Patients

| Reference | Study Design/ Country | CP Group/Controls | Results | Adverse Events | Strengths | Weaknesses |
|-----------|-----------------------|-------------------|---------|---------------|-----------|------------|
| Duan et al 20 | Case series/China | 10 severe COVID-19 pts/54 severe COVID-19 pts | - Clinical improvement and increase in O2 saturation within 3 days post-infusion. - Radiological and laboratory (Ly count and CRP) parameters improvement. | None | - Early experience - CP with high titer Nab (<1:640) | - Non RCT - Few patients enrolled |
| Perotti et al 21 | Prospective cohort study/Italy | 46 severe COVID-19 pts/23 severe COVID-19 pts | - Clinical, radiological and laboratory (CRP, LDH, ferritin) improvement at 7 days post-infusion. - Mortality reduction (from 15% to 6.5%). | 5 SAEs | - First report in western world - Homogeneous population of pts | - Non RCT - Few pts enrolled - Historical control group |
| Liu et al 22 | Propensity score-matched control study/China | 39 severe COVID-19 pts/12 and 14 matched control patients | - Significant reduction in oxygen requirements (OR 0.86; P=0.025) and mortality (HR 0.34; P=0.027) in CP-treated group. | None | - Large control population | - Retrospective non RCT |
| Salazar et al 23 | Prospective study (interim analysis)/USA | 136 COVID-19 pts/251 COVID-19 pts | - Significant reduction of 28-days mortality for CP pts transfused within 72 hours of hospitalization and with high anti-RBD titer. | NR | - Large sample size | - Interim analysis - Non RCT |
| Salazar et al 24 | Propensity score-matched study/USA | 31 COVID-19 pts/594 COVID-19 pts | - Early transfusion (≤ 44 hours after hospitalization) of CP reduced mortality. | 7 (5 mild and 2 severe) | - Large sample size | - Non RCT |
| Xia et al 25 | Case-control retrospective study/ China | 138 severe or LT COVID-19 pts/1568 severe or LT COVID-19 pts | - CP could improve the symptoms and mortality in COVID-19 pts. | NR | - Single center study - Large control population of pts | - Retrospective study |
| Rogers et al 26 | Matched cohort study | 64 severe COVID-19 pts/177 severe COVID-19 pts | - No significant difference in risk of mortality or rate of hospital discharge was observed. | 2 TRALI | - Single center study | - Non RCT |
| Ibrahim et al 27 | Prospective study/USA | 38 severe or LT COVID-19 pts/352 severe or LT COVID-19 pts | - Patients receiving CP early had significant lower mortality and shorter hospital length of stay than patients with more advanced COVID-19. | 1 SAE | - Homogenous population of pts | - Non RCT - Few pts enrolled |
| Abolghasemi et al 28 | Case-control study/Iran | 115 COVID-19 patients/74 COVID-19 patients | - A reduction in all-cause mortality and length of hospitalization was observed in CP-treated group. | 1 NSAE | - Homogenous - Non RCT | - Control group assignment |
| Joyner et al 29 | EAP/USA | 20,000 severe or LT COVID-19 pts/25,000 severe or LT COVID-19 pts | - Low 7-day mortality rate (8.6%), particularly when CP was administered early in the clinical course of COVID-19. | < 1% transfusion-related SAEs | - Large population of pts | - Non RCT - EAP - No untreated control arm |

(Continued)
Table 1 (Continued).

| Reference       | Study Design/ Country | CP Group/Controls | Results                                                                                                                                                                                                 | Adverse Events | Strengths | Weaknesses                                                                 |
|-----------------|-----------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------|----------------------------------------------------------------------------|
| Li et al.18      | RCT/China             | 52 severe or LT COVID-19 pts/51 severe or LT COVID-19 pts | - A significant clinical improvement was observed only in CP-treated group with severe COVID-19.                                                                                                                                                                 | 2 (1 SAE and 1 NSAE) | - RCT | - Prematurely halted - Late CP infusion (30 days from symptoms) - Few pts enrolled |
| Agarwal et al.19 | PLACID Trial          | 235 moderate COVID-19 pts/229 moderate COVID-19 pts | - CP was not associated with progression to severe COVID-19 or with reduction in mortality.                                                                                                                                                                      | 8 (4 SAEs and 3 NSAEs) | - RCT | - Not blinded RCT - CP with low-titer Nab (median: 1:40)                                                                       |
| Gharbharan et al.21 | RCT/Netherlands       | 43 COVID-19 pts/43 COVID-19 pts | - No differences in mortality, length of hospital stay or disease severity at day 15 were observed between the two study arms.                                                                                                                                 | No SAEs | - RCT | - Prematurely halted - Pts transfused with 1 CP unit                                                                         |
| Rasheed et al.21 | RCT/Iraq              | 21 COVID-19 pts/28 COVID-19 pts | - Mortality reduction in CP treated patients. - Better therapeutic results with CP with high SARS-CoV-2 IgG levels.                                                                                                                                       | 1 NSAE | - RCT | - Small trial - Not blinded                                                                                                   |
| Avendano-Sola et al.22 | RCT/Spain              | 38 COVID-19 pts/43 COVID-19 pts | - Reduction of mortality rate from 9% to 0% in CP group - No CP-treated patient progressed to mechanical ventilation.                                                                                                                                      | 2 SAEs | - RCT | - Prematurely halted - Few pts enrolled                                                                                         |
| Simonovich et al.23 | RCT/Argentina         | 228 COVID-19 pts/105 COVID-19 pts | - No differences in clinical status or overall mortality in CP-treated and control groups.                                                                                                                                                                     | 4.8% (1/228) | - RCT | - Only pts with severe pneumonia enrolled - No data on early administration of CP                                                 |

Abbreviations: Ly, lymphocyte; CRP, C-reactive protein; CP, convalescent plasma; Nab, neutralizing antibodies; RCT, randomized controlled trial; pts, patients; SAEs, severe adverse events; NSAEs, non-severe adverse events; LDH, lactate dehydrogenase; LT, life-threatening; OR, odds ratio; HR, hazard ratio; EAP, Expanded Access Program; RBD, receptor-binding domain; NR, not reported; TRALI, transfusion-related acute lung injury.
In a retrospective, propensity score-matched control study, Liu and colleagues assessed the efficacy of CP in severe COVID-19 patients. A significant reduction in oxygen requirements (adjusted odds ratio [OR] 0.86; P=0.025) and a survival improvement (adjusted hazard ratio [HR] 0.34; P=0.027) were observed in CP-treated patients versus controls.

In the interim analysis of the prospective study conducted by Salazar and colleagues on 136 COVID-19 CP-treated patients and 251 controls, a trend towards a benefit from CP was observed. Differences in mortality appeared to be larger among subgroups of patients who were transfused early (ie, within 72 hours of hospital admission) with high-titer CP (ie, anti-receptor binding domain [RBD] IgG titer ≥1:1350). These findings were successively confirmed by the same authors in a 60-day follow-up study conducted in the whole cohort of 351 CP transfused patients (Table 1).

Similar positive results were showed in the retrospective analysis by Xia and colleagues in patients with severe or critical COVID-19.

No significant difference in the mortality risk or in the rate of hospital discharge was observed by Rogers and colleagues between a group of patients treated with CP and control patients, although there was a suggestion of improved outcome among elderly patients.

The importance of the early administration of CP emerged from an analysis of the results of a study by Ibrahim and colleagues in the USA: COVID-19 patients who received CP early in their disease course had a significantly lower in-hospital mortality rate (13% vs 55%, P=0.02) and a shorter mean time spent in hospital (15.4 days versus 33 days, P<0.01) than those receiving CP later in the disease progression. These results were replicated in an Iranian case–control study by Abolghasemi and colleagues.

During the initial emergency period of the SARS-CoV-2 pandemic, the fastest method to obtain clinical results on CP use by investigators was that of performing retrospective exploratory analyses of patients given the treatment for compassionate use or in the frame of expanded access programs (EAPs). The largest EAP was that conducted by the US Food and Drug Administration (FDA) in collaboration with the Mayo Clinic, whose results have been published recently. This study analyzed the key safety metrics of 20,000 hospitalized patients with COVID-19 treated with CP. The incidence of serious adverse events related to CP transfusion was low (less than 1%) and the 7-day mortality was 8.6%, with greater beneficial clinical effects observed when CP was administered earlier in the clinical course of COVID-19.

To date, six RCT have been published on the use of CP in COVID-19.

An RCT of 103 patients with severe, life-threatening COVID-19 in China documented clinical improvement in 51.9% of patients treated with CP and in 43.1% of patients who received standard treatment, which was not a statistically significant difference (P=0.26). However, the trial was halted early because of the decrease in the number of patients with COVID-19 in China during the study period, which could have contributed to the study being underpowered to detect clinically significant results. Nevertheless, restricting the analysis only to patients with severe COVID-19, the difference in the primary outcome (clinical improvement) reached statistical significance (91.3% versus 68.2%, P=0.03).

In the PLACID RCT carried out in India, 464 patients with moderate COVID-19 were randomized to receive CP or the best standard of care. After the analysis of the results, the authors concluded that CP was not associated with a reduction in mortality or progression to severe COVID-19. Notably, three deaths possibly related to CP infusion were recorded. The main limitation of this study was the utilization of CP units with a low neutralizing antibody titer (median: 1:40).

An open-label RCT of CP versus standard of care, named the ConCOVID study, was conducted in the Netherlands. The trial was halted prematurely, when the baseline SARS-CoV-2 neutralizing antibody titers of participants and CP units transfused were found to be comparable, challenging the potential benefit of CP in the patients included in this study. In any case, no differences in mortality (P=0.95), time spent in hospital (P=0.68) or disease severity at day 15 (P=0.58) were observed between the study arms.

A small RCT performed by Rasheed and colleagues on 21 COVID-19 patients treated with CP and 28 controls showed a reduction in mortality rate in CP-treated group (1/21 versus 8/28, P=0.03).

A Spanish RCT trial showed a reduction in mortality rate in CP-treated patients compared to controls. Of note, no CP-treated patient progressed to mechanical ventilation. However, this study, too, was halted prematurely because of the fall in recruitment related to control of the pandemic.

Finally, a randomized RCT from Argentina enrolling 333 patients with severe COVID-19 (228 treated with CP and 105 controls) observed no significant differences in clinical status or overall mortality between patients receiving CP and those who received placebo.

All in all, the great majority of the studies selected on the basis of the number of patients enrolled and study
Table 2 Main Characteristics of the Systematic Reviews and Meta-Analyses on the Role of Convalescent Plasma in COVID-19 Patients

| Reference                | Date of Acceptance | Publication Type       | Number/Type of Studies Included | Number of Pts Evaluated | Main Conclusions                                                                 |
|--------------------------|--------------------|------------------------|--------------------------------|-------------------------|----------------------------------------------------------------------------------|
| Rajendran et al14        | 29 April 2020      | Systematic review      | 5/1 PT, 1 PC, 1 NR, 1 CR, 1 DS  | 27                      | - Convalescent plasma had a beneficial effect on symptoms and may reduce mortality  
|                          |                    |                        |                                |                          | - Increase in NAbT and disappearance of SARS-CoV-2 RNA was observed in almost all patients in CP therapy |
| Bakhtawar et al15        | 3 August 2020      | Systematic review      | 10/1 RCT, 1 PS, 1 RS, 2 CR, 5 CS | 156                     | - CP therapy produces notable improvements in patients' clinical symptoms and radiological and biochemical parameters associated with COVID-19 |
| Sarkar et al16           | 4 August 2020      | Systematic review/meta- | 7/2 RCT, 5 CS                   | 5444                    | - CP reduced mortality (OR 0.44; 95% CI 0.25–0.77), increased viral clearance (OR 11.29; 95% CI 4.9–25.9) and improved clinical symptoms (OR 2.06; 95% CI 0.8–4.9) when compared to baseline |
| Rabelo-da-Ponte et al17  | 6 August 2020      | Metadata analysis      | 9/NA                           | 149                     | - CP was associated with reduced viral loads (RR 0.13; 95% CI 0.09–0.18), C-reactive protein levels (ROM 0.11; 95% CI 0.01–0.86) and clinical improvement (ROM 0.53; 95% CI 0.36–0.79) was observed |
| Talae et al18            | 7 August 2020      | Systematic review/meta- | 7/NA                           | NA                      | - CP had significant beneficial effect on clinical improvement (RR 1.41,95% CI 1.01–1.98) and on negative conversion rate (RR 2.68; 95% CI 1.71–4.20)  
|                          |                    | analysis               |                                |                          | - A trend towards reduced mortality (RR 0.52; 95% CI 0.26–1.03) was observed |
| Wong et al19             | 14 August 2020     | Systematic review/meta- | 3/NA                           | NA                      | - CP significantly increased the viral nucleic acid negative conversion rate (RR 2.47; 95% CI 1.70–3.57) and tended to decrease mortality risk (RR 0.65; 95% CI 0.42–1.02) |
| Juul et al10             | 14 August 2020     | Systematic review/meta- | 2/2 RCT                        | 189                     | - No definitive evidence of a difference between CP versus standard care on all-cause mortality (RR 0.60; 95% CI 0.33–1.10)  
|                          |                    | analysis               |                                |                          | |
| Klassen et al19          | 29 October 2020    | Systematic review/meta- | 38/5 RCT, 13 MCS, 20 CS or CR   | 10,436                  | - Aggregated-data analysis showed a 51% reduction in mortality rate in patients transfused with CP compared to patients receiving standard treatments (OR 0.49; 95% CI 0.37–0.64) |
| Chai et al20             | 12 October 2020    | Systematic review/meta- | 19/2 RCT, 8 controlled NRS, 9   | 36,081                  | - Uncertainty regarding the safety and efficacy of CP basing on the available literature data. |

**Abbreviations:** CP, convalescent plasma; PT, pilot study; PC, preliminary communication; NR, novel report; CR, case report; DS, descriptive study; NAbT, neutralizing antibody titer; RCT, randomized controlled trial; CS, cohort studies; Pts, patients; OR, odds ratio; NA, not available; RR, risk ratio; ROM, ratio of mean; PS, prospective study; RS, retrospective study; MCS, matched-control studies; NRS, non-randomized studies.

design (12/16, 75%) showed a beneficial effect of CP treatment in severe COVID-19 patients in terms of clinical improvement and/or reduction of mortality risk. The high rate of biases (ie, small patient populations and study design) of these studies, including the RCTs, should, however, be highlighted.

**Systematic Reviews**

Several systematic reviews and meta-analyses on the use of CP in COVID-19 patients have already been published. However, given the continuing output of trials being published over time,44–52 the number of studies they include varies greatly according to the date of publication. Table 2 reports the main characteristics and conclusions of these systematic reviews according to the date of acceptance of the review.

The largest and most recent systematic review is the one pre-published by Klassen and colleagues.51 The authors identified a total of 38 studies including 5 RCTs, 13 matched-control studies and 20 case series or case reports for a total of 10,436 CODIV-19 patients. A pooled analysis of the outcome data showed a 51% reduction in mortality rate in patients transfused with CP compared to the rate in patients receiving standard treatments (OR 0.49; 95% CI 0.37–0.64).51
In addition to these reviews, some investigators, considering the rapidly evolving scenario, have performed periodically updated systematic literature assessments, named living systematic reviews and meta-analyses. Ref.50,52 The second living update of the Cochrane Systematic Review included 19 studies (2 RCTs and 17 non-randomized studies) evaluating 36,081 patients receiving CP. Ref.52 On the basis of the available data, the authors were unable to reach a conclusion on the safety and efficacy of CP treatment for COVID-19. However, they were optimistic regarding the achievement of conclusive information in a future update, considering the huge number of ongoing studies (138, of which 73 are RCTs). Ref.52

Conclusions
COVID-19 is the largest global public health crisis of the 21st century. Due to the non-availability of specific vaccines, at the moment, synthetic drugs and biologic therapies (ie, CP, hyperimmune immunoglobulin and monoclonal antibodies) are the only weapons with which to tackle the virus. Among the latter treatments, only CP is currently available. Although not conclusive, there is accumulating evidence indicating that CP is safe and effective in blocking the progression of COVID-19 and obtaining clinical improvement, when administered early in the course of the disease and when containing an adequate titer of neutralizing antibodies. The results of the many ongoing RCTs will shortly help us to definitively assess the role played by CP in the management of COVID-19 patients.

Disclosure
The authors report no potential conflicts of interest regarding this work.

References
1. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Viral J. 2019;16:69.
2. Chen Y, Liu Q, Guo D. Coronavirus: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. doi:10.1002/jmv.25681
3. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263–270. doi:10.1016/S0140-6736(03)13967-0
4. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi:10.1056/NEJMoa030747
5. de Groot RJ, Baker SC, Baric RS, et al. Commentary: middle east respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–7792. doi:10.1128/JVI.01244-13
6. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed November 10, 2020.
7. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036. doi:10.1136/bmj.m1036
8. Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020;11(1):5284. doi:10.1038/s41467-020-19056-6
9. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
10. WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 — interim WHO SOLIDARITY trial results. medRxiv. 2020. doi:10.1101/2020.10.25.209817
11. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
12. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Microbiol Rev. 2004;2:695–703. doi:10.1038/nrmicro9747
13. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38:e66–e73. doi:10.1097/CCM.0b013e3181d44c1e
14. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609. doi:10.7326/0003-4819-145-8-200610170-00139
15. Mair-Jenkins J, Sauvedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi:10.1093/infdis/jiu396
16. Salazar E, Christensen PA, Graviss EA, et al. Treatment of Coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290–2303. doi:10.1016/j.ajpath.2020.08.001
17. Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–1446. doi:10.1016/j.cmi.2020.08.005
18. Stevens RW, Rivera CG, Saleh OA. Time to treat: applying lessons learned from other viral syndromes to SARS-CoV-2. Mayo Clin Proc Innov Qual Outcomes. 2020;4:759–763. doi:10.1016/j.mayocpq.2020.09.010
19. Rojas M, Rodriguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:10.1016/j.autrev.2020.102554
20. Mekonnen D, Mengist HM, Derbie A, et al. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: a systematic review and meta-analysis. Rev Med Virol. 2020;5:2281. doi:10.1002/rmv.2281
21. Mazzini L, Martinuzzi D, Hyseni I, et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2020;27:112937.
22. Padoan A, Bonfante P, Pagliari M, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EbioMedicine. 2020;62:103101. doi:10.1016/j.ebiom.2020.103101
23. Bal A, Pozzetto B, Trabaud M-A, et al. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild COVID-19 patients: sensitivity, specificity and association with virus neutralization test. medRxiv. 2020. doi:10.1101/2020.09.30.20194290
